home | publications

2005 PUBLICATIONS

1. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L
Clin Chem 51(1) 102-12, 2005.
Abstract

2. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.
Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S.
Oncogene 2005 Mar 7.
Abstract

3. A methylation profile of in vitro immortalized human cell lines.
Liu L, Zhang J, Bates S, Li JJ, Peehl DM, Rhim JS, Pfeifer GP
Int J Oncol. 26(1): 275-85, 2005.
Abstract

4. Farnesyltransferase inhibitor effects on prostate tumor micro-enviroment and radiation survival.
Shi Y, Wu J, Mick R, Cerniglia GJ, Cohen-Jonathan E, Rhim JS, Koch CJ, Bernhard EJ
Prostate 62(1): 69-82, 2005.
Abstract

5. Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line.
Gu Y, Kim KH, Ko D, Srivastava S, Moul JW, McLeod DG, Rhim JS
Anticancer Res 25(1A):1-8, 2005.
Abstract

6. Proteomics in prostate cancer.
Bañez LL, Srivastava S, Moul JW
Curr Opin Urol. 15(3):151-6, 2005.
Abstract

7. Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer.
Brassell SA, Rosner IL, McLeod DG.
Curr Opin Urol. 2005 May;15(3):163-6.
Abstract

8. VEGF Inhibitors in Cancer Therapy.
Cardones AR and Bañez LL
Current Pharmaceutical Design, 11, 1-8, 2005.

9. Rationale for molecular biomarkers of prostate cancer.
Bañez LL, Srivastava S, Moul JW
Kirby, Partin, Feneley and Parsons (eds), Prostate Cancer: Principles and Practice, Taylor and Francis Medical Books, Abdington, U.K., 2005.

10. Quantitative Expression Profile of PSGR in Prostate Cancer.
Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW and Srivastava S
Prostate Cancer and Prostatic Diseases, 2005.

11. Androgen Receptor Binding Sites Identified by a GREF_GATA Model.
Katsuaki Masuda, Thomas Werner, Shilpi Maheshwari Matthias Frisch, Soyon Oh, Gyorgy Petrovics, Klaus May Vasantha Srikantan, Shiv Srivastava and Albert Dobi
J. Mol. Biol. (2005) 353, 763–771.

12. Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining and localizing biochemical recurrence of prostate cancer.
Ward JF, Moul JW
Curr Opin Urol., 2005, 15(3): 181-6.

13. Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer.
Ward JF, Moul JW
Curr Opin Urol., 2005, 15(3): 187-95.

14. Treating the biochemical recurrence of prostate cancer after Part III: Treating strategies for biochemical recurrence of prostate cancer.
Ward JF, Moul JW
Curr Opin Urol., 2005, 15(3): 187-95.

15. Cellular Prostatic Acid Phosphatase: A Protein Tyrosine phosphatase Involved in Androgen-independent proliferation of Prostate Cancer
Suresh Veeramani, Ta-Chun Yuan, Siu-Ju Chen, Fen-Fen Lin, Juliette E Petersen, Syed Shaheduzzaman, Shiv Srivastava, Richard G. Macdonald and Ming-Fong Lin
Endocrine-Related Cancer, 2005, 12:1-18.